Mainboard · BSE and NSEDraft filed
HINDUSTAN LABORATORIES LIMITED IPO: dates, price band, lot size, objects of the issue
Get updates on this IPO
Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.Dates, allotment, listing and analyst views. Stop anytime.
By continuing you agree to the Terms and Privacy policy
Key facts
- Price band
- Not announced
- Lot size
- Not announced
- Lot amount at the upper band
- Not announced
- Issue size at the upper band
- 1,41,00,000 shares (Amount not stated in the draft)
- DRHP dated Sat 3 Jan 2026, page 82
- Bid dates
- Not announced
- Listing date
- Not announced
- Proposed exchanges
- BSE and NSE
Timeline (IST)
- Draft filedTue 13 Jan 2026 confirmedDRHP dated Sat 3 Jan 2026
- OpensDates to be announced
- ClosesDates to be announced
- AllotmentDates to be announced
- Refund and unblockDates to be announced
- ListingDates to be announced
Objects of the issue
| Object | Amount |
|---|---|
| Funding the working capital requirements of our Company | ₹72.50 crore |
| General corporate purposes | Not stated in the draft |
| Total | Not stated in the draft |
The offer for sale goes to the selling shareholders, not the company. DRHP dated Sat 3 Jan 2026, page 107
Company and promoters
As described in the DRHP
We are an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a business-to-government (B2G) framework.
DRHP dated Sat 3 Jan 2026, page 24
Promoters
- 3 individual promoters
DRHP dated Sat 3 Jan 2026, page 24
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 99.99% | Not stated in the DRHP |
DRHP dated Sat 3 Jan 2026, page 101
Financials (restated)
| Item | For the period ended September 30, 2025 | For the year ended March 31, 2025 | For the year ended March 31, 2024 | For the year ended March 31, 2023 |
|---|---|---|---|---|
| Revenue from operations | ₹112.63 crore | ₹219.75 crore | ₹186.37 crore | ₹172.34 crore |
| Profit after tax | ₹18.24 crore | ₹41.27 crore | ₹34.14 crore | ₹22.25 crore |
| Net worth | ₹197.01 crore | ₹178.74 crore | ₹137.34 crore | ₹103.15 crore |
| Total borrowings | Not stated in the draft | Not stated in the draft | Not stated in the draft | Not stated in the draft |
DRHP dated Sat 3 Jan 2026, page 86
Who is selling in the offer for sale
| Selling shareholder | Type | Shares offered | Amount at the upper band |
|---|---|---|---|
| Individual shareholder | Individual | 91,00,000 | Not announced |
| Total offer for sale | Not stated in the draft | ||
DRHP dated Sat 3 Jan 2026, page 82
Peer comparison (as in the DRHP)
| Name of Company | Face Value (₹ per share) | P/E | EPS (₹) Basic | EPS (₹) Diluted | RoNW (%) | NAV (₹ per share) | Total income (₹ in million) |
|---|---|---|---|---|---|---|---|
| Hindustan Laboratories Limited | 10 | [●] | 8.28 | 8.28 | 26.11% | 35.85 | 2,273.72 |
| Ajanta Pharma Limited | 2 | 35.25 | 73.56 | 73.53 | 25.02% | 301.59 | 7,778.96 |
| Syncom Formulations (India) Limited | 1 | 25.70 | 0.57 | 0.57 | 15.69% | 3.64 | 4,824.47 |
| Windlas Biotech Limited | 5 | 25.70 | 29.19 | 28.87 | 12.76% | 243.18 | 47,426.00 |
Reproduced from the DRHP dated Sat 3 Jan 2026, page 118; InsightPier adds no figures
Risk factors
84 total- The company faces strong competition from other generic medicine suppliers in India (DRHP page 35)
- The business depends on a single manufacturing facility at Palghar and its operating risks (DRHP page 36)
- Most revenue comes from government customers won through tenders; losing them would hurt the business (DRHP page 36)
- A small number of customers account for much of the revenue (DRHP page 38)
- Future growth depends on adding new generic products on time and at reasonable cost (DRHP page 39)